{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:45:05Z","timestamp":1760237105260,"version":"build-2065373602"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40263-025-01209-0","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T10:05:35Z","timestamp":1755079535000},"page":"1157-1172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct02736656","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert L.","family":"Findling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Katic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Liebowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Waxmonsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Fry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peibing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilmiya","family":"Yarullina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulane","family":"Maldonado-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Rose","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"1","key":"1209_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1087054714539997","volume":"20","author":"JR Holbrook","year":"2016","unstructured":"Holbrook JR, Cuffe SP, Cai B, Visser SN, Forthofer MS, Bottai M, et al. Persistence of parent-reported ADHD symptoms from childhood through adolescence in a community sample. J Atten Disord. 2016;20(1):11\u201320.","journal-title":"J Atten Disord"},{"issue":"2","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142\u201351.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su7102a1","volume":"71","author":"RH Bitsko","year":"2022","unstructured":"Bitsko RH, Claussen AH, Lichstein J, Black LI, Jones SE, Danielson ML, et al. Mental health surveillance among children-United States, 2013\u20132019. MMWR Suppl. 2022;71(2):1\u201342.","journal-title":"MMWR Suppl."},{"key":"1209_CR4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.","edition":"5"},{"key":"1209_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-244X-2-9","volume":"2","author":"JR Altfas","year":"2002","unstructured":"Altfas JR. Prevalence of attention deficit\/hyperactivity disorder among adults in obesity treatment. BMC Psychiatry. 2002;2:9.","journal-title":"BMC Psychiatry"},{"issue":"7","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4088\/JCP.11m07529","volume":"73","author":"J Biederman","year":"2012","unstructured":"Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV. Adult outcome of attention-deficit\/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry. 2012;73(7):941\u201350.","journal-title":"J Clin Psychiatry"},{"key":"1209_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1741-7015-10-99","volume":"10","author":"M Shaw","year":"2012","unstructured":"Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.","journal-title":"BMC Med"},{"key":"1209_CR8","first-page":"3","volume":"64","author":"J Biederman","year":"2003","unstructured":"Biederman J. Pharmacotherapy for attention-deficit\/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003;64:3\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","volume":"174","author":"PD Quinn","year":"2017","unstructured":"Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877\u201385.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1542\/peds.2008-1597","volume":"123","author":"RM Scheffler","year":"2009","unstructured":"Scheffler RM, Brown TT, Fulton BD, Hinshaw SP, Levine P, Stone S. Positive association between attention-deficit\/ hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics. 2009;123(5):1273\u20139.","journal-title":"Pediatrics"},{"issue":"2","key":"1209_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116407","volume":"10","author":"LE Arnold","year":"2015","unstructured":"Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit\/hyperactivity disorder: a systematic review. PLoS ONE. 2015;10(2): e0116407.","journal-title":"PLoS ONE"},{"issue":"6","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.euroneuro.2012.07.016","volume":"23","author":"M Fredriksen","year":"2013","unstructured":"Fredriksen M, Halmoy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508\u201327.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1087054713486516","volume":"20","author":"V Harpin","year":"2016","unstructured":"Harpin V, Mazzone L, Raynaud JP, Kahle J, Hodgkins P. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016;20(4):295\u2013305.","journal-title":"J Atten Disord"},{"issue":"4","key":"1209_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4): e20192528.","journal-title":"Pediatrics"},{"issue":"5","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3810\/pgm.2014.09.2801","volume":"126","author":"DB Clemow","year":"2014","unstructured":"Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126(5):64\u201381.","journal-title":"Postgrad Med"},{"issue":"4","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1517\/13543784.2016.1147558","volume":"25","author":"A Childress","year":"2016","unstructured":"Childress A, Tran C. Current investigational drugs for the treatment of attention-deficit\/hyperactivity disorder. Expert Opin Investig Drugs. 2016;25(4):463\u201374.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1209_CR17","first-page":"192","volume":"21","author":"L Briars","year":"2016","unstructured":"Briars L, Todd T. A review of pharmacological management of attention-deficit\/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192\u2013206.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1209_CR18","unstructured":"United States Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions. Accessed 11 Dec 2023."},{"key":"1209_CR19","unstructured":"Qelbree. Prescribing information. Supernus Pharmaceuticals, Inc. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211964s013lbl.pdf. Accessed 11 June 2025."},{"issue":"3","key":"1209_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/cap.2024.0138","volume":"35","author":"A Childress","year":"2025","unstructured":"Childress A, Asubonteng K, Cox G, Earnest J, Hayman K, Yarullina I, et al. Viloxazine extended-release administered with psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder: a phase 4, open-label trial. J Child Adolesc Psychopharmacol. 2025;35(3):155\u201366.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1209_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/JEP.S433524","volume":"16","author":"J Garcia-Olivares","year":"2024","unstructured":"Garcia-Olivares J, Yegla B, Bymaster FP, Earnest J, Koch J, Yu C, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-deficit\/hyperactivity disorder. J Exp Pharmacol. 2024;16:13\u201324.","journal-title":"J Exp Pharmacol"},{"key":"1209_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JEP.S256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300.","journal-title":"J Exp Pharmacol"},{"key":"1209_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuint.2015.02.001","volume":"82","author":"E Banerjee","year":"2015","unstructured":"Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52\u201368.","journal-title":"Neurochem Int"},{"issue":"38","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"11993","DOI":"10.1523\/JNEUROSCI.2513-09.2009","volume":"29","author":"MJ Crockett","year":"2009","unstructured":"Crockett MJ, Clark L, Robbins TW. Reconciling the role of serotonin in behavioral inhibition and aversion: acute tryptophan depletion abolishes punishment-induced inhibition in humans. J Neurosci. 2009;29(38):11993\u20139.","journal-title":"J Neurosci"},{"issue":"215","key":"1209_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2012.03.065","volume":"26","author":"JW Dalley","year":"2012","unstructured":"Dalley JW, Roiser JP. Dopamine, serotonin and impulsivity. Neuroscience. 2012;26(215):42\u201358.","journal-title":"Neuroscience"},{"issue":"2","key":"1209_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1087054719836159","volume":"24","author":"JK Johnson","year":"2020","unstructured":"Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348\u201358.","journal-title":"J Atten Disord"},{"issue":"4","key":"1209_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","volume":"41","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452\u201366.","journal-title":"Clin Ther"},{"issue":"4","key":"1209_CR29","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clinthera.2021.01.027","volume":"43","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684\u2013700.","journal-title":"Clin Ther"},{"issue":"2","key":"1209_CR30","first-page":"43","volume":"51","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43\u201364.","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"1209_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-024-01356-0","volume":"44","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liranso T, Maldonado-Cruz Z, Kosheleff AR, Nasser A. Impact of viloxazine extended-release capsules (Qelbree(\u00ae) on select cytochrome P450 enzyme activity and evaluation of CYP2D6 genetic polymorphisms on viloxazine pharmacokinetics. Clin Drug Investig. 2024;44(5):303\u201317.","journal-title":"Clin Drug Investig"},{"issue":"6079","key":"1209_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/bmj.2.6079.96-a","volume":"2","author":"JG Edwards","year":"1977","unstructured":"Edwards JG. Convulsive seizures and viloxazine. Br Med J. 1977;2(6079):96\u20137.","journal-title":"Br Med J"},{"issue":"9","key":"1209_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp.47.9.960","volume":"47","author":"JG Edwards","year":"1984","unstructured":"Edwards JG, Glen-Bott M. Does viloxazine have epileptogenic properties? J Neurol Neurosurg Psychiatry. 1984;47(9):960\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1209_CR34","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. CDC Growth Charts: Percentile Data Files with LMS Values. 2000 [cited; Available from: Available from: https:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm. Accessed 11 Dec 2023."},{"key":"1209_CR35","first-page":"1","volume":"63","author":"KM Flegal","year":"2013","unstructured":"Flegal KM, Cole TJ. Construction of LMS parameters for the Centers of Disease Control and Prevention 2000 growth charts. Natl Health Stat Report. 2013;63:1\u20133.","journal-title":"Natl Health Stat Report."},{"key":"1209_CR36","unstructured":"Centers for Disease Control and Prevention. 2011\u20132021 Youth Risk Behavior Surveillance System (YRBSS). Available from: www.cdc.gov\/yrbs. Accessed 11 Dec 2023."},{"issue":"3","key":"1209_CR37","first-page":"16","volume":"71","author":"S Everett Jones","year":"2022","unstructured":"Everett Jones S, Ethier KA, Hertz M, DeGue S, Le VD, Thornton J, et al. Mental health, suicidality, and connectedness among high school students during the COVID-19 pandemic\u2014adolescent behaviors and experiences survey, United States, January\u2013June 2021. Centers for Dis Control Prev Morbidity Mortality Wkly Report. 2022;71(3):16\u201321.","journal-title":"Centers for Dis Control Prev Morbidity Mortality Wkly Report."},{"issue":"7","key":"1209_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24664","volume":"7","author":"DA Ruch","year":"2024","unstructured":"Ruch DA, Horowitz LM, Hughes JL, Sarkisian K, Luby JL, Fontanella CA, et al. Suicide in US preteens aged 8 to 12 years, 2001 to 2022. JAMA Netw Open. 2024;7(7): e2424664.","journal-title":"JAMA Netw Open"},{"key":"1209_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jad.2020.01.075","volume":"266","author":"C Siffel","year":"2020","unstructured":"Siffel C, DerSarkissian M, Kponee-Shovein K, Spalding W, Gu YM, Cheng M, et al. Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit\/hyperactivity disorder. J Affect Disord. 2020;266:109\u201319.","journal-title":"J Affect Disord"},{"issue":"3","key":"1209_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/15374416.2024.2335625","volume":"53","author":"ML Danielson","year":"2024","unstructured":"Danielson ML, Claussen AH, Bitsko RH, Katz SM, Newsome K, Blumberg SJ, et al. ADHD prevalence among U.S. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. J Clin Child Adolesc Psychol. 2024;53(3):343\u201360.","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"6","key":"1209_CR41","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.jval.2024.03.897","volume":"27","author":"A Chorniy","year":"2024","unstructured":"Chorniy A, Hurwitz JT, Grizzle A, Young J, Gopakumar S, Earnest J. EPH68 baseline characteristics of pediatric and adult patients with ADHD prescribed viloxazine ER, stimulants or atomoxetine, in open claims data. Value in Health. 2024;27(6):S165.","journal-title":"Value in Health."},{"key":"1209_CR42","unstructured":"Strattera. Prescribing information. Eli Lilly; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021411s035lbl.pdf. Accessed 11 Dec 2023."},{"key":"1209_CR43","unstructured":"Azstarys. Prescribing information. Corium, Inc.; 2021. https:\/\/azstarys-pro.com\/. Accessed 13 Dec 2023."},{"key":"1209_CR44","unstructured":"Adderall. Prescribing information. Teva Pharmaceuticals; 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021303s026lbl.pdf.. Accessed 11 Dec 2023."},{"key":"1209_CR45","unstructured":"Concerta. Prescribing information. Janssen Pharmaceuticals, Inc.; 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CONCERTA-pi.pdf. Accessed 11 Dec 2023."},{"key":"1209_CR46","unstructured":"Vyvanse. Prescribing information. Shire US, Inc.; 2017. Accessed December 13, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208510lbl.pdf.. Accessed 13 Dec 2023."},{"key":"1209_CR47","unstructured":"Focalin XR. Prescribing Information. Novartis Pharmaceuticals; 2017. Accessed December 11, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021802s033lbl.pdf.. Accessed 11 Dec 2023."},{"issue":"1","key":"1209_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/cap.2011.0088","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(1):11\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"1209_CR49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/CHI.0b013e318193060e","volume":"48","author":"C Donnelly","year":"2009","unstructured":"Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2009;48(2):176\u201385.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1209_CR50","unstructured":"Adler L LV, Yarullina I, Brijbasi L, Rubin J. Viloxazine ER for adults with attention-deficit\/hyperactivity disorder and mood symptoms: results of a decentralized, open-label, phase IV trial. In: Poster presented at American Psychiatric Association Annual Meeting;. May 17-21, 2025; Los Angeles, CA."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01209-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:04:34Z","timestamp":1760173474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01209-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"10 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work and its open access publication were funded by Supernus Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.L.F. receives or has received research support, acted as a consultant and\/or has received honoraria from Abbvie, Ajna, Akili, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Bioprojet, BioXcel, Bristol Myers Squibb,Corium, Elsevier, Intra-Cellular Therapies, Iqvia, Karuna, Lundbeck, Maplight, Merck, MJH Life Sciences, NIH, Novartis, Otsuka, Oxford University Press, PaxMedica, PCORI, Pfizer, Radius, Sage, Signant Health, Sumitomo Pharma, Sunovion, Supernus Pharmaceuticals, Takeda, Tris, Viatris, and Xenon. Over the past 3 years, J.W. has received research support from Supernus and served as a consultant for Iron Shore and Adlon Pharmaceuticals. M.L. is a consultant for Vistagen Therapeutics and Newleos Pharma, and in the past 3 years has conducted clinical trials for Supernus, Alto, Biohaven, Janssen, Otsuka, Compass, Abbvie, and Relmada. A.K. has received honoraria from Supernus and in the past 3 years has conducted clinical research for Abbvie, Axsome, Boehringer Ingelheim, Cingulate, Corium, Janssen, Otsuka, Pfizer, Relmada, and Supernus. N.F., P.Q., I.Y., Z.M-C., V.R.L., and J.R. are employees of Supernus Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation (ICH) Good Clinical Practice Guidelines for biomedical research, and the United States (US) Code of Federal Regulations (21 CFR). The central IRB (Advarra) approved the trial protocol under Pro00026366.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Each participant\u2019s parent or legal guardian signed an informed consent form (ICF); participants signed an informed assent form, and those turning 18 years of age during the trial also signed an ICF.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data are not available in a repository, but data will be made available upon reasonable request directed to jrubin@supernus.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design: R.L.F. Methodology and data collection: R.L.F., J.W., A.K., N.F., and M.L. Analysis and interpretation: R.L.F., J.W., I.Y., Z.M.C., V.R.L., P.Q., and J.R. Writing, review, and editing: R.L.F., M.L., J.W., I.Y., Z.M.C., V.R.L., P.Q., and J.R. All authors read and approved the final submitted manuscript and agree to be accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}